Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INX-08189 in Treatment-Naive Genotype 2 and 3 Hepatitis C
NCT01425970Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2012
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-986094 in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoints: Change in Hepatitis C Viral Load Measurements at Week 48, Sustained Virologic Response at 12 weeks post-treatment and 2 more. Started May 2012; status: terminated.
02
Drugs
BMS-986094
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01425970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01425970.